鹅肌肽通过CCL5介导的肝细胞-CD44+ pDC互作恢复肝硬化抗菌免疫
该研究通过肝硬化小鼠单细胞测序及功能实验,发现CD44+浆细胞样树突状细胞(pDC)亚群耗竭导致抗菌免疫受损。鹅肌肽可上调肝细胞CCL5表达,经CCL5-CCR5轴招募pDC,恢复其经TLR7/9分泌IFN-α激活巨噬细胞清除细菌。人多组学数据及CATCH-LIFE队列验证了上述指标与感染发生率及临床结局的相关性。
要点
- 肝硬化时CD44+ pDC亚群显著耗竭,是抗菌免疫缺陷的关键环节。
- 鹅肌肽通过上调肝细胞CCL5,经CCL5-CCR5轴招募pDC恢复抗菌防御。
- CCL5、鹅肌肽及CD44+ pDC水平与肝硬化患者感染发生及临床结局相关。
核心结论
- 研究揭示鹅肌肽-CCL5-pDC-巨噬细胞代谢免疫轴在肝硬化中严重受损,恢复该网络是肝硬化相关感染的预测与治疗新策略。
研究设计与样本
- 对对照与肝硬化小鼠(伴或不伴细菌感染)肝脏行单细胞RNA测序,并用流式细胞术、靶向代谢组学及功能实验验证。
- 功能实验包括离体共培养、体内过继转移、抗体阻断和转基因小鼠模型。
- 利用GEO人源bulk及单细胞转录组数据集,并在全国多中心前瞻性临床队列CATCH-LIFE中验证。
主要发现
- 肝硬化中负责抗菌免疫的CD44+ pDC亚群显著耗竭。
- CD44+ pDC不直接杀细菌,而是通过TLR7/9感知病原体分泌I型IFN-α,刺激巨噬细胞趋化、活性氧产生和细菌吞噬。
- 肝脏CD44+ pDC的募集由CCL5-CCR5轴调控,该轴由特定CCL5相关肝细胞亚群(小鼠以Mup11为标志) orchestrated。
- 靶向代谢组学发现肝硬化中耗尽的组氨酸代谢物鹅肌肽可内源性上调肝细胞CCL5表达。
- 补充鹅肌肽成功恢复肝细胞-pDC保护轴,显著降低肝硬化小鼠细菌负荷和死亡率。
关键数值与推荐
- 人多组学数据及CATCH-LIFE队列显示,CCL5、鹅肌肽和CD44+ pDC水平与肝硬化患者感染发生率及临床结局显著相关。
临床怎么用
- 鹅肌肽补充或靶向CCL5-pDC轴有望作为精准治疗降低肝硬化感染相关死亡率。
- CCL5、鹅肌肽及CD44+ pDC水平可能用于预测肝硬化患者感染风险及临床结局。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with cirrhosis exhibit increased susceptibility to bacterial infections; however, the specific immune defects facilitating this vulnerability remain incompletely understood. We aimed to characterize the dysregulated intercellular crosstalk within the cirrhotic liver that compromises antibacterial defense. METHODS: We performed single-cell RNA sequencing (scRNA-seq) on livers from control and cirrhotic mice with or without bacterial infection. Inferred cellular interactions were validated using flow cytometry, targeted metabolomics, and functional assays, including ex vivo co-culture, in vivo adoptive transfer, antibody blockade, and transgenic mouse models. Clinical relevance and mechanistic conservation were established utilizing human bulk and single-cell transcriptomic datasets from GEO, alongside validation in a nationwide multicenter prospective clinical cohort (CATCH-LIFE). RESULTS: scRNA-seq and functional assays revealed a significantly depleted CD44+ plasmacytoid dendritic cell (pDC) subpopulation responsible for impaired antibacterial immunity in cirrhosis. Mechanistically, CD44+ pDCs do not kill bacteria directly; rather, they sense pathogens via TLR7/9 to secrete type I IFN-α, which subsequently stimulates macrophage chemotaxis, reactive oxygen species production, and bacterial phagocytosis. The hepatic recruitment of CD44+ pDCs is governed by the CCL5-CCR5 axis, orchestrated by a specific subset of CCL5-associated hepatocytes (marked by Mup11 in mice). Targeted metabolomics identified that anserine, a histidine metabolite depleted in cirrhosis, intrinsically upregulates hepatocyte CCL5 expression. Anserine supplementation successfully restored the hepatocyte-pDC protective axis, significantly reducing bacterial burden and mortality in cirrhotic mice. Finally, multi-omics human data and the CATCH-LIFE cohort demonstrated that levels of CCL5, anserine, and CD44+ pDCs were significantly correlated with infection incidence and clinical outcomes in patients with cirrhosis. CONCLUSION: We uncover a novel anserine-CCL5-pDC-macrophage metabolic-immune axis that is critically impaired in cirrhosis. Restoring this network offers a promising predictive and therapeutic strategy for cirrhosis-associated infections. IMPACT AND IMPLICATIONS: Patients with cirrhosis face a critically high risk of bacterial infections, yet the specific immune defects driving this susceptibility have remained elusive. This study uncovers a novel metabolic-immune mechanism wherein the histamine metabolite anserine potentiates a protective crosstalk between hepatocytes and CD44+ plasmacytoid dendritic cells (pDCs). We demonstrate that this axis relies on conserved CCL5-CCR5 signaling to recruit pDCs, which subsequently orchestrate bacterial clearance via TLR7/9-mediated IFN-α secretion and macrophage activation. Importantly, these findings were validated in a multi-center prospective human cohort, showing that anserine, CCL5 and CD44+ pDC levels significantly correlate with infection incidence and clinical outcome. This uncovers a previously unrecognized metabolic-immune vulnerability in cirrhosis and suggests that anserine supplementation or targeting the CCL5-pDC axis could serve as a precision therapy to decrease infection-related mortality in cirrhosis.
引用
- Chen R, Li J, Zhong X, et al. Anserine restores antibacterial immunity in cirrhosis via protective CCL5-mediated hepatocyte-CD44+ pDC crosstalk. J Hepatol. 2026. PMID: 42385859. doi:10.1016/j.jhep.2026.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。